BACKGROUND: Involvement of epidermal growth factor (EGF) is reported in diseases caused by hypoxia. Its functional polymorphism may alter its transcription, affecting EGF expression, contributing to obstructive sleep apnea (OSA). OBJECTIVE: The aim of this study was to investigate associations of EGF+61 polymorphism and risk of OSA. METHODS: Two hundred two participants were enrolled in this case-control study. DNA was extracted from peripheral blood, and EGF 61A/G polymorphism was determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. RESULTS: No significant association between EGF 61 A/G polymorphism and risk of OSA was observed in any of the gene models tested (AA vs. GG: OR = 0.97, 95% CI = 0.37-2.55; P = 0.95). However, compared with GG genotype, AG genotype associated with decreased risk of severe OSA (AG vs. GG: OR = 0.32, 95% CI = 0.11-0.94). CONCLUSIONS: Our study showed that AG genotype has a protective effect on OSA patients against severe disease, although EGF 61A/G polymorphisms have no role on the risk of the disease. Additional large studies should further validate our findings.
BACKGROUND: Involvement of epidermal growth factor (EGF) is reported in diseases caused by hypoxia. Its functional polymorphism may alter its transcription, affecting EGF expression, contributing to obstructive sleep apnea (OSA). OBJECTIVE: The aim of this study was to investigate associations of EGF+61 polymorphism and risk of OSA. METHODS: Two hundred two participants were enrolled in this case-control study. DNA was extracted from peripheral blood, and EGF 61A/G polymorphism was determined using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. RESULTS: No significant association between EGF 61 A/G polymorphism and risk of OSA was observed in any of the gene models tested (AA vs. GG: OR = 0.97, 95% CI = 0.37-2.55; P = 0.95). However, compared with GG genotype, AG genotype associated with decreased risk of severe OSA (AG vs. GG: OR = 0.32, 95% CI = 0.11-0.94). CONCLUSIONS: Our study showed that AG genotype has a protective effect on OSA patients against severe disease, although EGF 61A/G polymorphisms have no role on the risk of the disease. Additional large studies should further validate our findings.
Authors: Majid Shahbazi; Vera Pravica; Najma Nasreen; Hana Fakhoury; Anthony A Fryer; Richard C Strange; Peter E Hutchinson; Joy E Osborne; John T Lear; Andrew G Smith; Ian V Hutchinson Journal: Lancet Date: 2002-02-02 Impact factor: 79.321
Authors: Francisco das Chagas Abreu da Silveira; Bruno de Almeida Lopes; Clovis Orlando da Fonseca; Thereza Quirico-Santos; Izabel Christina Nunes de Palmer Paixão; Lidia Maria da Fonte de Amorim Journal: J Cancer Res Clin Oncol Date: 2012-04-06 Impact factor: 4.553
Authors: Antonio Grilo; Elena S Ruiz-Granados; Concha Moreno-Rey; Jose M Rivera; Agustin Ruiz; Luis M Real; Maria E Sáez Journal: Gene Date: 2013-03-21 Impact factor: 3.688
Authors: Robert Kieszko; Paweł Krawczyk; Tomasz Powrózek; Aneta Szudy-Szczyrek; Michał Szczyrek; Iwona Homa; Jadwiga Daniluk; Janusz Milanowski Journal: Arch Med Sci Date: 2015-04-28 Impact factor: 3.318